[go: up one dir, main page]

NO20075927L - IL-21 varianter - Google Patents

IL-21 varianter

Info

Publication number
NO20075927L
NO20075927L NO20075927A NO20075927A NO20075927L NO 20075927 L NO20075927 L NO 20075927L NO 20075927 A NO20075927 A NO 20075927A NO 20075927 A NO20075927 A NO 20075927A NO 20075927 L NO20075927 L NO 20075927L
Authority
NO
Norway
Prior art keywords
amino acids
variants
deleting
seq
peptide
Prior art date
Application number
NO20075927A
Other languages
English (en)
Inventor
Siv Annegrethe Hjorth
Kent Bodensgaard
Dennis Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20075927L publication Critical patent/NO20075927L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det er tilveiebrakt en IL-21 variant hvori aminosyrene er blitt deletert og/eller substituert i regionen som består av aminosyre nr. 65 til 96.
NO20075927A 2005-04-18 2007-11-19 IL-21 varianter NO20075927L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500562 2005-04-18
PCT/EP2006/061635 WO2006111524A2 (en) 2005-04-18 2006-04-18 Il-21 variants

Publications (1)

Publication Number Publication Date
NO20075927L true NO20075927L (no) 2007-12-07

Family

ID=36950214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075927A NO20075927L (no) 2005-04-18 2007-11-19 IL-21 varianter

Country Status (17)

Country Link
US (2) US8034326B2 (no)
EP (2) EP2360181B1 (no)
JP (2) JP2008538290A (no)
KR (1) KR20080013878A (no)
CN (1) CN101180315A (no)
AT (1) ATE497975T1 (no)
AU (1) AU2006237329B2 (no)
BR (1) BRPI0609079A2 (no)
CA (1) CA2604222A1 (no)
DE (1) DE602006020032D1 (no)
ES (1) ES2357550T3 (no)
IL (1) IL186265A0 (no)
MX (1) MX2007012887A (no)
NO (1) NO20075927L (no)
RU (1) RU2412199C2 (no)
WO (1) WO2006111524A2 (no)
ZA (1) ZA200708407B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
RU2412199C2 (ru) 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
WO2008074863A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
EP2123676A4 (en) * 2007-01-05 2011-01-05 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
WO2010076339A1 (en) * 2009-01-05 2010-07-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
JP6395379B2 (ja) 2011-01-18 2018-09-26 バイオニズ リミテッド ライアビリティー カンパニー γｃサイトカイン活性を調節するための組成物および方法
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CA3000207A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma-c-cytokine activity
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
PE20250757A1 (es) 2017-08-03 2025-03-13 Amgen Inc Muteinas de interleucina 21 y metodos de tratamiento
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
KR20200110358A (ko) 2018-01-12 2020-09-23 암젠 인크 항-pd-1 항체 및 치료 방법
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN111205361B (zh) * 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020269255A1 (en) 2019-05-03 2022-01-06 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN115232797A (zh) * 2021-04-23 2022-10-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
IL308609A (en) * 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
KR20230044130A (ko) 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
TW202409068A (zh) * 2022-06-29 2024-03-01 大陸商北京星奇原生物科技有限公司 Ｉｌ—２１多肽和使用方法
CN117210411A (zh) * 2023-09-13 2023-12-12 中国科学院生物物理研究所 一种免疫细胞及其表达载体、应用和制备方法
WO2025109155A1 (en) * 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
HU206897B (en) 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
WO1989001029A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Airlift insect cell culture
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
US5494662A (en) 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
JP2002505338A (ja) 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
DK1974747T3 (da) 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
BR0008772B1 (pt) 1999-03-09 2011-11-01 vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
EP2130919A1 (en) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
JP2005525302A (ja) 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
EP1531850B1 (en) 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
AU2003282955A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
ATE448298T1 (de) 2002-12-13 2009-11-15 Zymogenetics Inc Il-21-produktion in prokaryontischen wirten
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
MXPA05012313A (es) 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
CA2529520A1 (en) * 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
DK1692276T3 (da) 2003-11-19 2010-11-01 Us Gov Health & Human Serv Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
AU2005244942A1 (en) 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
JP2008508885A (ja) 2004-08-05 2008-03-27 ワイス インターロイキン−２１受容体活性を中和すること
RU2412199C2 (ru) * 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
WO2008074863A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor

Also Published As

Publication number Publication date
ATE497975T1 (de) 2011-02-15
EP1877439A2 (en) 2008-01-16
BRPI0609079A2 (pt) 2010-11-16
ZA200708407B (en) 2008-10-29
US20090035254A1 (en) 2009-02-05
MX2007012887A (es) 2007-12-10
ES2357550T3 (es) 2011-04-27
WO2006111524A3 (en) 2006-12-07
EP1877439B1 (en) 2011-02-09
AU2006237329B2 (en) 2012-04-12
IL186265A0 (en) 2008-01-20
EP2360181B1 (en) 2013-09-18
WO2006111524A2 (en) 2006-10-26
JP2008538290A (ja) 2008-10-23
US20120082996A1 (en) 2012-04-05
DE602006020032D1 (de) 2011-03-24
EP2360181A1 (en) 2011-08-24
US8034326B2 (en) 2011-10-11
CN101180315A (zh) 2008-05-14
US8383367B2 (en) 2013-02-26
RU2007136026A (ru) 2009-05-27
KR20080013878A (ko) 2008-02-13
JP2012070742A (ja) 2012-04-12
RU2412199C2 (ru) 2011-02-20
AU2006237329A1 (en) 2006-10-26
CA2604222A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20075927L (no) IL-21 varianter
DK1476541T3 (da) Cytokin (zcytor17-ligand)
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
DE602005008996D1 (de) Radiofluorierte peptide
EP2865387A3 (en) Priming of an immune response
NZ596658A (en) Dig-10 insecticidal cry toxins
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
DE602007004110D1 (de) Hausstaubmilbenallergen
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
DK2076532T3 (da) Cytokinderivater
ITMI20030789A1 (it) Valvola di iniezione di comustibile.
BRPI0413437A (pt) preparação de peptìdeos de somatostatina
EP1497307A4 (en) P.FALCIPARUM MEROZOITE PROTEIN-1 42 AS A RECOMBINANT VACCINE
EP1567542A4 (en) NEW MULTI-TENANT PEPTIDE COMPOSITIONS RELATED TO INHIBINE INCREASING THE PRODUCTION PERFORMANCE OF BIRDS
EP2004352A4 (en) AMINO ACID SUPPLEMENT FOR PEPTIDE CONSTRUCTIONS
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
ATE414905T1 (de) Diabetesmodell
GB0409559D0 (en) Polypeptide
DE602006017806D1 (de) Behandlung von neurodegeneration
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
DK1794294T3 (da) Rekombinant carboxypeptidase B
FR2874025B1 (fr) Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application